Baxter International (NYSE:BAX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $0.60 per share and revenue of $2.82 billion for the quarter. Baxter International has set its Q2 2025 guidance at 0.590-0.630 EPS and its FY 2025 guidance at 2.470-2.550 EPS.
Baxter International (NYSE:BAX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.14. Baxter International had a negative net margin of 4.71% and a positive return on equity of 17.24%. The company had revenue of $2.63 billion for the quarter, compared to the consensus estimate of $2.59 billion. During the same quarter in the previous year, the firm posted $0.65 EPS. The business's revenue was up 5.4% compared to the same quarter last year. On average, analysts expect Baxter International to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Baxter International Stock Performance
Shares of NYSE:BAX traded up $0.46 on Friday, hitting $29.23. 4,031,150 shares of the company were exchanged, compared to its average volume of 4,666,913. The company's 50 day moving average price is $30.02 and its two-hundred day moving average price is $31.17. Baxter International has a one year low of $26.25 and a one year high of $40.49. The company has a debt-to-equity ratio of 1.33, a quick ratio of 1.40 and a current ratio of 2.02. The firm has a market capitalization of $15.00 billion, a price-to-earnings ratio of -26.57, a PEG ratio of 0.85 and a beta of 0.61.
Baxter International Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Investors of record on Friday, August 29th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 dividend on an annualized basis and a yield of 2.33%. Baxter International's payout ratio is currently -61.82%.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Citigroup lowered their target price on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 9th. Evercore ISI reduced their price target on shares of Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Morgan Stanley decreased their price target on shares of Baxter International from $28.00 to $27.00 and set an "underweight" rating on the stock in a research note on Tuesday, July 15th. Wells Fargo & Company decreased their price target on shares of Baxter International from $36.00 to $33.00 and set an "equal weight" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen raised shares of Baxter International from a "hold" rating to a "buy" rating in a research note on Sunday, June 22nd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $36.38.
Check Out Our Latest Analysis on Baxter International
About Baxter International
(
Get Free Report)
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.
See Also
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
